Immunic Inc will hold a virtual research and development day on September 9 focused on relapsing multiple sclerosis (MS). The event will feature company executives and MS specialists discussing vidofludimus calcium (IMU-838), an oral therapy under Phase 3 ENSURE trials with topline results expected by the end of 2026. The therapy targets both inflammatory and neurodegenerative aspects of MS. This event aims to provide insights into the treatment's potential and the MS patient journey.
Sysco Corporation and Teamsters Locals 630 and 848 have agreed on wages, benefits, and pension terms, but the strike continues due to union demands allowing strikes at any time, risking service disruptions in Los Angeles. Sysco offered an $8 hourly w...
SkyAI, Inc. announced a cash tender offer to buy up to 95% of its common stock and warrants at $3.00 per share, representing a 65% premium over its recent closing price. The offer, expected to start around October 15, 2026, aims to provide liquidity ...
Upbit exchange has introduced new trading pairs for the Reserve Rights (RSR) token, allowing it to be traded against the Korean won and Tether's USDT stablecoin. This expansion provides users with more options by offering both fiat and stablecoin quo...
Billionaire Adam Weitsman purchased 117 Pudgy Penguins NFTs to support the struggling collection after its parent company shut down the Abstract layer-2 project. This move increased his total Pudgy Penguins holdings to 167 and coincided with a 16.7% ...
American billionaire Adam Weitsman purchased 117 Pudgy Penguins NFTs over the weekend to support the collection and boost community confidence during a challenging period. This move coincided with a 125.66% increase in weekly Pudgy Penguins NFT sales...
